Zobrazeno 1 - 10
of 56
pro vyhledávání: '"M. Teresa Cibeira"'
Autor:
Anna deDaniel, Luis Gerardo Rodríguez‐Lobato, Natalia Tovar, M. Teresa Cibeira, David F. Moreno, Aina Oliver‐Caldés, Ignacio Isola, Ester Lozano, Joan Bladé, Laura Rosiñol, Carlos Fernández de Larrea
Publikováno v:
HemaSphere, Vol 8, Iss 5, Pp n/a-n/a (2024)
Abstract The 2/20/20 International Myeloma Working Group (IMWG) score is the most employed risk score in clinical practice to evaluate the risk of progression from smoldering multiple myeloma (SMM) to symptomatic multiple myeloma. However, it faces a
Externí odkaz:
https://doaj.org/article/1de8802a875642aa8d1b51cf74359b01
Autor:
Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, Paolo Milani, Arnaud Jaccard, Frank Bridoux, Meletios A. Dimopoulos, Sriram Ravichandran, Ute Hegenbart, Wilfried Roeloffzen, M. Teresa Cibeira, Hermine Agis, Monique C. Minnema, Rui Bergantim, Roman Hájek, Cristina João, Alexandros Leonidakis, Giorgos Cheliotis, Pieter Sonneveld, Efstathios Kastritis, Ashutosh Wechalekar
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Systemic light-chain (AL) amyloidosis is a rare and debilitating disease. Advances have been made in new treatments in recent years, yet real-world data on the management of the disease are scarce. EMN23 is a retrospective, observational stu
Externí odkaz:
https://doaj.org/article/b66ddf1ad30c445e87c57bf515f577a5
Autor:
Paolo Milani, M. Teresa Cibeira
Publikováno v:
Hemato, Vol 3, Iss 1, Pp 98-108 (2022)
Light chain amyloidosis is a complex disease where a small B-cell clone produces a monoclonal immunoglobulin light chain that causes deposits and specific organ dysfunction. The available treatment strategies aim to reduce or eliminate amyloidogenic
Externí odkaz:
https://doaj.org/article/557fd46ca7324f3da22f294413034bce
Autor:
Aina Oliver-Caldes, Juan Carlos Soler-Perromat, Ester Lozano, David Moreno, Alex Bataller, Pablo Mozas, Marta Garrote, Xavier Setoain, Juan Ignacio Aróstegui, Jordi Yagüe, Natalia Tovar, Raquel Jiménez, Luis Gerardo Rodríguez-Lobato, M. Teresa Cibeira, Laura Rosiñol, Joan Bladé, Manel Juan, Carlos Fernández de Larrea
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionMultiple myeloma (MM) is considered an incurable hematological neoplasm. For transplant-eligible patients, initial treatment includes an induction phase followed by an autologous stem cell transplantation (ASCT). Despite the introduction
Externí odkaz:
https://doaj.org/article/e5fabab14d0d45a2ac2c95f79c8116fd
Autor:
Ashutosh D. Wechalekar, M. Teresa Cibeira, Simon D. Gibbs, Arnaud Jaccard, Shaji Kumar, Giampaolo Merlini, Giovanni Palladini, Vaishali Sanchorawala, Stefan Schönland, Christopher Venner, Mario Boccadoro, Efstathios Kastritis
Publikováno v:
Amyloid. 30:3-17
This guideline has been developed jointly by the European Society of Haematology and International Society of Amyloidosis recommending non-transplant chemotherapy treatment for patients with AL amyloidosis.A review of literature and grading of eviden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f335e2a2112138c50c7a887b2bd13c7
https://doi.org/10.1080/13506129.2022.2093635
https://doi.org/10.1080/13506129.2022.2093635
Autor:
Laura Rosiñol, Elena Cuadrado, Nuria Esforzado, Fritz Diekmann, Natalia Castrejón de Anta, David Cucchiari, Natalia Tovar, Alicia Molina-Andujar, M. Teresa Cibeira, Frederic Cofan, Ignacio Revuelta, Joan Bladé, Luis F. Quintana, Carlos Fernández de Larrea
Publikováno v:
American Journal of Kidney Diseases. 78:755-759
Monoclonal immunoglobulin deposition disease (MIDD) usually leads to kidney failure. Treatment of patients with a bortezomib-based regimen followed by autologous stem cell transplantation (SCT) has been increasingly used, with improvements in the res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7199d447ba8d7e8c1b1d84059f3660c7
https://doi.org/10.1053/j.ajkd.2021.02.337
https://doi.org/10.1053/j.ajkd.2021.02.337
Autor:
Luis Gerardo Rodríguez-Lobato, Anna de Daniel i Bisbe, Natalia Tovar, Raquel Jiménez-Segura, M. Teresa Cibeira, David F. Moreno, Aina Oliver-Caldes, Alexandra Martínez-Roca, Ester Lozano, Joan Bladé Creixenti, Laura Rosinol Dachs, Carlos Fernandez de Larrea
Publikováno v:
Blood. 140:4341-4342
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b94972f72e570a42fefdf4fd7a0e454d
https://doi.org/10.1182/blood-2022-165371
https://doi.org/10.1182/blood-2022-165371
Autor:
Luis Gerardo Rodríguez-Lobato, Oriol Cardus, Joan Mañe-Pujol, Anthony M Battram, Lorena Pérez-Amill, Hugo Calderón, Beatriz Martin-Antonio, Aina Oliver-Caldes, Agnès Garcias-López, Ester Lozano, David F. Moreno, Valentín Ortiz-Maldonado, Maria Queralt Salas, Anna de Daniel i Bisbe, Natalia Tovar, Raquel Jiménez-Segura, M. Teresa Cibeira, Laura Rosinol Dachs, Joan Bladé Creixenti, Manel Juan, Álvaro Urbano-Ispizua, Pablo Engel, Carlos Fernandez de Larrea
Publikováno v:
Blood. 140:10281-10282
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e703213af6162c55d2c4d16ac1ba438b
https://doi.org/10.1182/blood-2022-166764
https://doi.org/10.1182/blood-2022-166764
Autor:
Jin Lu, Kenshi Suzuki, Edward N. Libby, Dominique Chauveau, Xiang Qin, Giovanni Palladini, Hans C. Lee, Naresh Bumma, Katharine S. Gries, Moshe E. Gatt, Raymond L. Comenzo, Sandra Y. Vasey, Brendan M. Weiss, Jason Valent, Michael Rosenzweig, Arnaud Jaccard, Monique C. Minnema, Peter Mollee, Vaishali Sanchorawala, Meral Beksac, Jessica Vermeulen, Simon D. J. Gibbs, Kihyun Kim, Ashutosh Wechalekar, Christopher P. Venner, John Fastenau, Brenda Tromp, Stefan Schönland, Namphuong Tran, Vania Hungria, Sandy W. Wong, Giampaolo Merlini, M. Teresa Cibeira, Efstathios Kastritis
Publikováno v:
Blood. 136:37-40
Background: Systemic AL amyloidosis is a rare disease characterized by amyloid fibril deposits, most commonly in the heart and kidneys; there are currently no health authority-approved treatments. Therapies for the treatment of multiple myeloma (MM),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58aeaf75e83a764541519175f2965f85
https://doi.org/10.1182/blood-2020-139438
https://doi.org/10.1182/blood-2020-139438
Autor:
Verónica Cánovas, Victoria Dourdil, Elham Askari, Ramón Lecumberri, Sunil Lakhwani, Mercedes Gironella, María E González-García, Luis E Tamariz, José Sarrá, Ángel Ramírez-Payer, María S Infante, Adrian Alegre, Maialen Sirvent, Virginia Pradillo, Cristina Martínez-Bilbao, M. Teresa Cibeira, Isabel Krsnik, Fernando Escalante, Marta S González-Pérez
Publikováno v:
Amyloid. 27:163-167
Management of patients with relapsed or refractory (R/R) AL amyloidosis is complex. Some initial reports have shown positive results with daratumumab in heavily pre-treated AL amyloidosis patients. In this retrospective multicentric study, 38 patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::751b71d47061f051b23cedd2a579a9f6
https://doi.org/10.1080/13506129.2020.1730791
https://doi.org/10.1080/13506129.2020.1730791